fbpx
Saturday, April 10, 2021

Israeli Prof Says Anti-Parasite Drug Could Be Effective Against COVID-19

Aaron Bandler is a staff writer for the Jewish Journal, mainly covering anti-Semitism and anti-Israel bias. Originally from the Bay Area, his past work experience includes writing for The Daily Wire, The Daily Caller and Townhall.

https://jewishjournal.com/wp-content/uploads/2020/04/jj_avatar.jpg
Aaron Bandler
Aaron Bandler is a staff writer for the Jewish Journal, mainly covering anti-Semitism and anti-Israel bias. Originally from the Bay Area, his past work experience includes writing for The Daily Wire, The Daily Caller and Townhall.

Eli Schwartz, a professor and founder of Sheba Medical Center’s Center for Travel Medicine and Tropical Disease, told The Jerusalem Post on June 15 that a drug used to treat parasitic infections could be effective in treating COVID-19.

The drug, Ivermectin, kills parasites in the body that can cause infections such as scabies and river blindness. Schwartz said that he started to look into the drug after President Donald Trump touted hydroxychloroquine as a potential therapeutic to fight the virus. On June 15, the FDA revoked its emergency-use authorization for hydroxychloroquine and chloroquine for the treatment of COVOD-19.

“We decided to look more widely for other medications and considered a few drugs that might have antiviral activity,” Schwartz said.

He is launching a study to test the drug’s efficacy on COVID-19 patients; he’s hopeful it will be completed in a few months. So far, 26 people have signed up for the study.

Schwartz believes that Ivermectin could eradicate the virus from a patient’s body in six days.

“The majority of people who get positive results have to be out of life (segregated from the public),” he said. “If [Ivermectin] works, they could take medication for a few days instead and be cured.”

Bangladesh Medical College and Hospital (BMCH) has observed some effectiveness in the use of Ivermectin in combination with the antibiotic doxycycline on COVID-19 patients. The combination has been used on 60 patients; the patients recovered from the virus in 10-11 days, on average.

However, BMCH Head of Medicine professor Tarek Alam told the Hindustan Times that Ivermectin is not effective on COVID-19 patients that have severe symptoms.

“As it works reducing replication of the novel coronavirus in the patient’s body at the early stage, our physicians gave the drug to those police personnel who start showing symptoms even if they were not tested,” he said.

Additionally, Australia’s Monash Biomedicine Discovery Institute released a paper in April finding that Ivermectin could kill the virus in 48 hours.

“We found that even a single dose could essentially remove all viral RNA by 48 hours and that even at 24 hours there was a really significant reduction in it,” the institute’s Dr. Kylie Wagstaff said in a statement at the time. “Ivermectin is very widely used and seen as a safe drug. We need to figure out now whether the dosage you can use it at in humans will be effective — that’s the next step.”

As of this writing, there are 19,122 confirmed COVID-19 cases in Israel and 302 deaths from the virus. Israel has seen a spike in cases since the country started reopening the economy; senior health official Sigal Sadetzky told Kan public broadcaster on June 15, “Right now, we don’t have markers to detect who is spreading the virus, as we did in the beginning. We don’t know where we need to be particularly careful, and where we need to carry out more tests — and this is the problem.”

Advertisment

Did you enjoy this article?

You'll love our roundtable.

Select list(s) to subscribe to


By submitting this form, you are consenting to receive marketing emails from: Jewish Journal, 3250 Wilshire Boulevard, Los Angeles, CA, 90010, http://www.jewishjournal.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Enjoyed this article?

You'll love our roundtable.

Select list(s) to subscribe to


By submitting this form, you are consenting to receive marketing emails from: Jewish Journal, 3250 Wilshire Boulevard, Los Angeles, CA, 90010, http://www.jewishjournal.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Editor's Picks

Latest Articles

Culture

Latest Articles
Latest

CUNY Student Senate to Vote on Resolution Rejecting IHRA

The resolution is being pushed by the CUNY Jewish Law Students Association and CUNY Students for Justice in Palestine in response to a March resolution adopting IHRA.

Biden’s Push for Restoring Aid to Palestinians Faces Legal Hurdles and Brewing Political Crisis

The new administration is pushing more fiscal aid and a return to the negotiating table as Palestinians head for elections in May.

Drone Deliveries to Launch in Tel Aviv By Year’s End

Simplex Interactive is taking part in an Israel-wide pilot program aimed at establishing a commercial drone network.

The Girl with the Funny Hair

Hair comes and goes. Yet we think it is who we are. 

Local Rabbi Introduces Social Media Star David Portnoy to Tefillin

David Portnoy, founder of Barstool Sports digital media, got more than he bargained for after recently taping one of his popular “One Bite” pizza reviews on Fairfax Blvd

Hollywood

Podcasts

More news and opinions than at a Shabbat dinner, right in your inbox.

Select list(s) to subscribe to


By submitting this form, you are consenting to receive marketing emails from: Jewish Journal, 3250 Wilshire Boulevard, Los Angeles, CA, 90010, http://www.jewishjournal.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

x